Skip to main content

Drug Interactions between cangrelor and enoxaparin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

enoxaparin cangrelor

Applies to: enoxaparin and cangrelor

MONITOR CLOSELY: Concomitant use of cangrelor with anticoagulants, thrombolytic agents, or other antiplatelet agents may theoretically increase the risk of bleeding. According to the manufacturer, cangrelor has been formally studied with unfractionated heparin and aspirin in healthy study subjects with no evidence of a pharmacokinetic or pharmacodynamic interaction. In clinical trials, cangrelor has been coadministered with bivalirudin, low molecular weight heparin, clopidogrel, prasugrel, and ticagrelor without clinically detectable interactions.

MANAGEMENT: Caution is recommended if cangrelor must be used in patients treated with other agents that alter hemostasis. Patients should be monitored for potentially increased bleeding complications.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2015) "Product Information. Kengreal (cangrelor)." The Medicines Company

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer